DarioHealth (DRIO) announced publication of a new peer-reviewed study in JMIR Cardio demonstrating that data-driven nudges delivered via Dario’s digital health platform are associated with significant and sustainable improvements in blood pressure, or BP, outcomes. The study analyzed real-world BP data from platform users whose health was tracked over time, comparing a cohort that received digital intervention messages to a propensity-matched control group. Key findings were that among users with high BP, those receiving digital nudges experienced a statistically significant reduction in monthly average systolic blood pressure three months after the intervention vs. a smaller reduction in the control group. Users reporting higher lifestyle activity levels further achieved greater systolic blood pressure reduction, underscoring the additive benefit of behavioral engagement in conjunction with digital nudges. This research provides important real-world clinical evidence that personalized, data-driven digital interventions can meaningfully reduce blood pressure in individuals with hypertension – and help maintain healthy BP levels in individuals without overt hypertension. By improving BP control across populations, digital health platforms like Dario have the potential to reduce downstream cardiovascular risks, lower costs associated with complications and improve overall population health.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DRIO:
- DarioHealth announces 79 new accounts signed year-to-date
- DarioHealth announces publication of study in JMIR on digital health platform
- DarioHealth price target raised to $11 from 60c at TD Cowen
- DarioHealth price target lowered to $16 at Stifel after reverse stock split
- DarioHealth Reports Q3 2025 Financial Results
